Between August 22 and August 28, thirteen BSE-listed small-cap stocks posted gains for five consecutive trading sessions, delivering cumulative returns that ranged from 20% to as high as 45%. The rally was led by companies in the consumer discretionary and pharma segments, with each security advancing at least 2% on the final day of the run-up. 9% over the same period, the small-cap index outperformed by a wide margin, underscoring a pronounced divergence between the two segments.
Analysts attribute the outperformance to a combination of factors: fresh capital inflows into the small-cap space, better-than-expected earnings reports from a few key players, and the lingering optimism around the recent fiscal stimulus measures that favour lower-priced equities. In addition, the relative neglect of small-caps by foreign institutional investors has left room for domestic retail money to chase higher yields, especially as large-cap valuations remain stretched. For the average Indian investor, the six-week surge highlights both opportunity and caution.
While the upside potential appears attractive, small-cap stocks are inherently more volatile and can reverse sharply if market sentiment shifts. Investors should treat these picks as a tactical addition to a diversified portfolio, limit exposure to a modest percentage of their equity allocation, and conduct thorough due-diligence before committing capital. Maintaining a balanced approach can help capture gains without exposing the portfolio to undue risk.